Une étude de phase 3 comparant l'efficacité du L19TNF + doxorubicine par rapport à la doxorubicine seule comme traitement de première ligne chez les patients atteints de sarcome des tissus mous avancé ou métastatique

Essai clinique

Type : Industriel
Statut : Ouvert
Phase : III
Étape du traitement : Traitements combinés
Date d'ouverture : 29/11/2017
Date clôture : 31/12/2024
Promoteur : Philogen S.p.A.
Progression du cancer: Loco-régional et à distance
Résumé :

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma patients.

In the study, 102 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2).

The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin (Arm 2) given for unresectable or metastatic soft tissue sarcoma improves efficacy measured as progression free survival, as compared to doxorubicin alone (Arm 1).

Domaines/spécialités :
  • Sarcomes (tissus mous et os)
Pathologies :
  • Angiosarcome du foie - Cim10 : C223
  • Autres tumeurs malignes du tissu conjonctif et autres tissus mous du thorax - Cim10 : C4938
  • Autres tumeurs malignes du tissu conjonctif et autres tissus mous de l'abdomen - Cim10 : C4948
  • Autres tumeurs malignes du tissu conjonctif et autres tissus mous du bassin - Cim10 : C4958
Liens externes :

Critères de population

Sexe : Homme et femme
Age minimum : 18 ans
Age maximum : 75 ans
Critères d’inclusion :
  1. Patients aged 18-75 years.

  2. Patients must have histological evidence of advanced unresectable and/or metastatic high-grade soft tissue sarcoma (grade 2 - 3 according to the FNLCC grading system) not amenable to curative treatment with surgery or radiotherapy. The following tumor types are included:

    • Malignant fibrous histiocytoma
    • Myxoid and round cell liposarcoma, pleomorphic liposarcoma or dedifferentiated
    • Liposarcoma
    • Pleomorphic rhabdomyosarcoma
    • Myxofibrosarcoma intermediate and high-grade
    • Fibrosarcoma
    • Leiomyosarcoma
    • Angiosarcoma
    • Alveolar rhabdomyosarcoma
    • Unclassified sarcoma NOS

    The following tumor types will not be included:

    • GIST
    • Mixed mesodermal tumor
    • Chondrosarcoma
    • Synovial sarcoma
    • Malignant peripheral nerve sheath tumor
    • Epithelioid sarcoma
    • Embryonal rhabdomyosarcoma
    • Malignant mesothelioma
    • Neuroblastoma
    • Osteosarcoma
    • Ewing's sarcoma / primitive neuroectodermal tumor
    • Desmoplastic small round cell tumor
    • Alveolar soft part sarcoma
  3. Patients must have at least one unidimensionally measurable lesion by computed tomography as defined by RECIST criteria 1.1. This lesion should not have been irradiated during previous treatments.
  4. Life expectancy of at least 3 months.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  6. Documented negative test for HIV-HBV-HCV. For HBV serology: the determination of HBsAg, anti-HBsAg-Ab and anti-HBCAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  7. Negative serum pregnancy test for females of childbearing potential* within 14 days of starting treatment.
  8. Informed consent signed and dated to participate in the study.
  9. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
Critères d’exclusion :
  1. Prior therapy (except surgery and radiation) for unresectable or metastatic malignant soft tissue sarcoma.
  2. Previous treatment with anthracycline-containing chemotherapy.
  3. Radiotherapy within 4 weeks prior to therapy.
  4. Known history of allergy to TNFα, anthracyclines or other intravenously administered human proteins/peptides/antibodies.
  5. Absolute neutrophil count (ANC) < 1.5 x 109/L, platelets < 100 x 109/L and haemoglobin (Hb) < 9.0 g/dl.
  6. Chronically impaired renal function or creatinine ≥ 2.0 x ULN.
  7. Inadequate liver function (ALT, AST, ALP or total bilirubin ≥ 2.5 x ULN.
  8. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  9. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  10. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).
  11. Clinically significant cardiac arrhythmias or requiring permanent medication.
  12. Uncontrolled hypertension, despite optimal therapy.
  13. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  14. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  15. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
  16. Pregnancy or breast-feeding.
  17. Requirement of chronic administration of corticosteroids or other immunosuppressant drugs. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
  18. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  19. Known active or latent tuberculosis (TB).
  20. Concurrent malignancies other than Soft Tissue Sarcoma, unless the patient has been disease-free for at least 2 years.
  21. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  22. Serious, non-healing wound, ulcer or bone fracture.
  23. Allergy to study medication or excipients in study medication.
  24. Concurrent therapy with anticoagulants.
  25. Concurrent use of other anti-cancer treatments or agents other than study medication.

Centre d'investigation

En cours
Nom : Centre Georges François Leclerc - CGFL
Ville : DIJON (21)
RESPONSABLE MÉDICAL
Nom : Dr HERVIEU
Prénom : Alice
Téléphone : Non disponible
Email : AHervieu@cgfl.fr
CONTACT TECHNIQUE
Nom : DEMIREL
Prénom : Serife
Téléphone : 03 80 73 77 51
Email : sdemirel@cgfl.fr

Référentiels Oncologik

Aucun référentiel n'est lié à cet essai.